SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on May 13, 2016. The filing reports corporate governance changes effective as of the report date. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Board Resignation: Hugh Dunkerley resigned from the Board of Directors and the Compensation Committee on May 13, 2016.
- Reason for Departure: The resignation was not the result of any disagreements with the Company's operations, policies, or practices.
- Board Composition: The Board size was reduced from seven members to six members.
- Committee Appointment: Reid Dabney, a current Board member, was appointed to the Compensation Committee. He remains the chairperson of the Audit Committee and the Company's Audit Committee financial expert.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risks. The only contingency noted is that Mr. Dunkerley will not stand for re-election at the Annual Meeting of Shareholders scheduled for June 2, 2016.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors and the Compensation Committee following the reduction to six members.
- Verify the status of the Audit Committee leadership under Reid Dabney.
- Review the attached Exhibit 99.1 (Letter of resignation) for any additional details not summarized in the main text.
- Check subsequent filings for the outcome of the June 2, 2016, Annual Meeting of Shareholders.